With a new program, Philadelphia is willing to provide same-day pay to people who clear the Americans with Disabilities Act -- or ADA - compliant ramps along city sidewalks to make traversing these ...

Starbucks is revamping its loyalty program and one of the new twists is that you can keep your rewards stars from expiring. The revamped program will launch on March 10 with three free membership ...

Yale University today announced significant enhancements to its financial aid program for undergraduates that will lower costs for future students and their families. The changes, which will go into ...

A popular California program designed to help people buy their first home is making a comeback. California's Dream For All program is reopening applications next month, offering down payment ...

People who interact with chatbots for emotional support or other personal reasons are likelier to report symptoms of depression or anxiety, a new study finds. The researchers from Mass General Brigham ...

Investors in Maze Therapeutics Inc (Symbol: MAZE) saw new options begin trading this week, for the March 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

The First Trust Nasdaq Artificial Intelligence and Robotics ETF is rated a 'Buy' for capturing a structural value shift in AI and robotics. ROBT's equal-weighted, tiered construction reduces ...

Vivoo's attachable smart toilet sensor was unveiled at CES 2026 and is designed to analyze hydration levels in real time. Corin Cesaric is a Flex Editor at CNET. She received her bachelor's degree in ...

Google launched the Android a-MAZE-ing Collectible, a 3-inch transparent figure with a built-in green maze where users tilt it to guide a metal ball through the puzzle. Priced at $24 plus shipping ...

Here’s a fun build from [RootSaid] that is suitable for people just getting started with microcontrollers and robotics — an Arduino-controlled two-wheeled robot. The video assumes you already have one ...

Ideaya Biosciences Inc. has submitted an IND application to the FDA for IDE-574, a KAT6/7 dual inhibitor with potential to treat hormone receptor-positive breast cancer and lung adenocarcinoma. A ...

The average one-year price target for Maze Therapeutics (NasdaqGM:MAZE) has been revised to $44.12 / share. This is an increase of 11.37% from the prior estimate of $39.61 dated November 14, 2025. The ...